ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
9 announcements with these filters
Dr. Reddy’s Laboratories will hold a board meeting on October 23, 2026, to approve the standalone and consolidated financial results for the quarter ending September 30, 2026.
Dr. Reddy's signed an exclusive distribution agreement with Takeda for Qdenga dengue vaccine in India's private market. No upfront consideration stated; availability expected H1 2027.
Dr. Reddy's confirmed a news report regarding a voluntary licensing agreement with Gilead Sciences for an HIV prevention drug, noting it is not material.
Dr. Reddy's Laboratories received two observations from the USFDA following a records assessment of its API manufacturing facility in Jiutepec, Mexico.
Dr. Reddy's Laboratories allotted 375 equity shares to employees upon the exercise of stock options under its ESOP scheme.
Dr. Reddy's Laboratories allotted 4,110 equity shares to employees under its 2002 Employee Stock Option Scheme. The shares rank pari passu with existing equity.
ICICI Prudential Mutual Fund acquired 7,12,884 shares of Dr. Reddy's Laboratories via the open market. This transaction increased the fund's total stake to 5.037%.
Dr. Reddy's Laboratories announced the resignation of Deepak Sapra, CEO of API and Services, effective November 12, 2026.
Dr. Reddy's Laboratories has terminated its distribution and promotion agreement with Novartis India Limited following a change in NIL's controlling shareholding.